Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307682 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,775
- Enrollment target
NCT02307682 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 1,775 participants.
The verdict
NCT02307682, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,775 participants
- Enrollment target
Study Summary
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
Interventions
- DRUG Brolucizumab ophthalmic solution
- DRUG Aflibercept ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,775 participants |
| Start Date | 2014-12-08 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02307682
The ClinicalTrials.gov registry entry for NCT02307682 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,775 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brolucizumab ophthalmic solution is the first listed.
NCT02307682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02307682 about?
NCT02307682 is a clinical study titled "Efficacy and Safety of RTH258 Versus Aflibercept - Study 1". The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-re...
What is the current status of trial NCT02307682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,775 participants. The study started on 2014-12-08. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT02307682?
The interventions under investigation include: Brolucizumab ophthalmic solution (DRUG), Aflibercept ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02307682?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.